CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia

NCT06622694 PHASE1 RECRUITING

This trial is exploratory research aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD13-02, a universal CD7 CAR T therapy, in subjects with relapsed/refractory severe aplastic anemia (SAA)

Details

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	PHASE1
Status	RECRUITING
Enrolment	15
Start date	Thu Jun 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Dec 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Severe Aplastic Anemia
• Relapse
• Refractory
• CAR T-cell Therapy

Interventions

• RD13-02

Countries

China